Remetinostat
Small moleculeexperimental
Clinical trial activity
4 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2011 (NCT01433731)
Timeline
Indications
Mechanism of action
- Histone deacetylase 2INHIBITOR
HDAC2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- shp-141
- shp-141
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02636244 | Phase 2 | Feb 1, 2017 | TetraLogic Pharmaceuticals |
| NCT02213861 | Phase 2 | Nov 1, 2014 | TetraLogic Pharmaceuticals |
| NCT01646567 | Phase 1 | Sep 1, 2012 | TetraLogic Pharmaceuticals, The Alfred Hospital |
| NCT01433731 | Phase 1 | Nov 1, 2011 | Northwestern University, PPD, TetraLogic Pharmaceuticals, The Leukemia and Lymphoma Society, Therapeutics, Inc., Veristat, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| TetraLogic Pharmaceuticals | For profit | 4 | 4 | 2 | 2011 |
| Northwestern University | Academic/Hospital | 1 | 0 | 1 | 2011 |
| PPD | For profit | 1 | 0 | 1 | 2011 |
| The Alfred Hospital | Academic/Hospital | 1 | 0 | 1 | 2012 |
| The Leukemia and Lymphoma Society | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Therapeutics, Inc. | For profit | 1 | 0 | 1 | 2011 |
| Veristat, Inc. | For profit | 1 | 0 | 1 | 2011 |
7 organizations
Page 1 / 1